

Corium, LLC
Notice to Covered Entities

Corium, LLC (“Corium”) recently recalculated 340B Ceiling Prices for the NDCs referenced below for the time of 2Q 2022 through 1Q 2025. As a result of the recalculation, Corium has determined that a refund is or may be due to 340B Covered Entities that purchased any of the below NDCs during the above time.

| Product Description | NDC |
|--|---------------|
| AZSTARYS 26.1 mg/5.2 mg Capsules | 65038-0286-99 |
| AZSTARYS 39.2 mg/7.8 mg Capsules | 65038-0429-99 |
| AZSTARYS 52.3 mg/10.4 mg Capsules | 65038-0561-99 |
| ADLARITY 5 mg/day adhesive transdermal system | 65038-0055-03 |
| ADLARITY 10 mg/day adhesive transdermal system | 65038-0056-03 |

Corium will send directly to 340B Covered Entity of record refunds for any amount equal to or in excess of \$50 (aggregated for all applicable NDCs) for the time listed above. Corium will notify those 340B Covered Entities at the address listed in the Health Resources and Services Administration (“HRSA”) database.

Covered Entities who may be owed less than \$50 in aggregate or who have questions about the above-referenced recalculation for aforementioned time may contact Corium via email at MarketAccess@corium.com. These communications should identify the relevant NDC(s) and time(s). Corium has asked HRSA to post this notice on the HRSA’s public website to give affected Covered Entities that may be owed less than \$50 an opportunity to request refunds.

Corium is committed to compliance with the 340B statute and to supporting the goals of the 340B Program. If you have any questions, please contact MarketAccess@corium.com.